We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49 | -1.65% | 29.26 | 29.25 | 29.52 | 29.73 | 29.20 | 29.71 | 6,646,430 | 22:20:00 |
From May 2019 to May 2024
By Patrick Costello
Roche Holding AG (RO.EB) said Wednesday that it has extended the offer period for its planned acquisition of the Philadelphia-based biotechnology company Spark Therapeutics Inc. (ONCE) to Sept. 3.
The Swiss pharmaceuticals company said the offer has been extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their review of Roche's pending acquisition of the company.
Roche said both parties remain committed to the deal and are working cooperatively with the FTC and CMA.
Roche's offer of $114.50 a share for all shares of Spark has been extended multiple times since it was announced in February and was set to expire Wednesday, July 31.
As of July 30, shareholders representing roughly 25.2% of Spark's outstanding shares had accepted Roche's offer, it added.
Write to Patrick Costello at patrick.costello@dowjones.com.
(END) Dow Jones Newswires
July 31, 2019 01:33 ET (05:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
